Key Takeaways:
- AbbVie Inc. (ABBV, Financial) delivers a strong start to 2025, exceeding earnings expectations.
- Analyst consensus points to a potential 15.17% upside, with a one-year average target price of $213.68.
- GF Value suggests a downside, estimating the stock's fair value at $167.84.
AbbVie Inc. (ABBV) kicked off 2025 on a high note, with impressive Q1 results that have captured the attention of investors. The company's adjusted earnings per share soared to $2.46, exceeding market expectations. This growth was underpinned by a remarkable 21% increase in its ex-Humira platform, pushing total revenue beyond $13.3 billion. Reflecting their confidence, AbbVie raised its full-year revenue guidance by $700 million, now projecting $59.7 billion.
Wall Street Analysts Forecast
The insights from 24 seasoned analysts reveal an optimistic outlook for AbbVie's stock. Over the next year, the average target price is set at $213.68, with predictions ranging between a high of $251.00 and a low of $173.00. This average target signifies a potential upside of 15.17% from the current trading price of $185.54. Investors seeking more detailed projections can explore the AbbVie Inc (ABBV, Financial) Forecast page.
Further supporting this outlook, 27 brokerage firms have collectively assigned AbbVie an average recommendation of 2.0, categorizing it as an "Outperform." This recommendation system uses a scale where 1 indicates a Strong Buy, and 5 represents a Sell.
Contrastingly, the GF Value projection offers a more cautionary perspective. GuruFocus estimates AbbVie's fair value in one year at $167.84, suggesting a possible downside of 9.54% from its current price. The GF Value is a crucial metric derived from the company's historical trading multiples, past business performance, and future growth estimates. For a deeper dive into AbbVie's financials, one can visit the AbbVie Inc (ABBV, Financial) Summary page.
